BioShares Biotechnology Clinical Trials ETF Company Profile

Description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the BioShares Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its total assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The fund is non-diversified.